CRO and analytics giant IQvia, the product of the IMS Health-Quintiles merger, quietly purchased UK-based bioinformatics company Linguamatics a month ago.
BioMérieux will adapt Invisible Sentinel's Veriflow DNA signature capturing technology on its Gene-Up system for food pathogen detection.
ArcherDX plans to keep its research and development efforts in its current facility and move its clinical and commercial testing operations to Baby Gene's CLIA lab.
Labcyte has developed an acoustic droplet ejection technology called Echo that uses sound energy for the contactless transfer of samples and reagents.
Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.
Arbor Biosciences' portfolio includes custom DNA microarrays and oligonucleotide libraries, as well as a line of targeted sequencing panels.
With the acquisition, Qiagen will integrate N-of-One’s MarkerMine database into its core technology to help customers design new, targeted therapies.
The company also reaffirmed its guidance for the fourth quarter, and continues to expect revenues of $46.5 million to $48.0 million and EPS of $.09 to $.11.
The index's 13 percent gain was below the 39 percent surge of 2017 but occurred despite the poor performance of index stocks in December.
The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.
The World Health Organization has announced the members of its gene-editing committee, according to NPR.
DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.
The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.
In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.